Abstract
BackgroundProgrammed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors can cause unique immune-related adverse effects due to non-specific immunological activation. However, less is known about adverse effects of these drugs...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have